LOGIN  |  REGISTER
Viking Therapeutics
Compass Therapeutics

Calliditas Therapeutics to present at upcoming investor conferences

November 07, 2023 | Last Trade: US$40.00 0.00 0.00

STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT)(Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the following conferences:

  • The Jefferies London Healthcare Conference, November 14-16 2023, in London, UK. CEO Renee Aguiar-Lucander will present at 2pm GMT on Wednesday 15 November.
  • The Stifel Healthcare Conference 2023, November 15 2023, in New York, USA.
    President of North America, Andrew Udell, will take part in a fireside chat at 10:10am ET on Wednesday 15 November.
  • The SEB Healthcare Seminar, November 21 2023, in Stockholm, Sweden.
  • The Piper Sandler 35th Annual Healthcare Conference, November 28-30 2023 in New York, NY, USA.

CEO Renée Aguiar-Lucander will also be speaking on a panel on Day 2 of the FT Global Pharma & Biotech Summit, which is taking place in November 7 - 9 2023 in London, UK. The Panel `Exploring Options for Strategic Partnerships' will take place at 11:05am GMT on Wednesday 8 November.

For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

The information was sent for publication, through the agency of the contact persons set out above, on November 7, 2023, at 16:00 p.m. CET.

The following files are available for download:

Terns Pharmaceuticals

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB